Oral semaglutide is the same GLP-1 medication found in Ozempic and Wegovy, made into a daily tablet. Because semaglutide is a peptide that stomach acid and enzymes normally break down, the tablet includes an absorption enhancer (SNAC) that helps a small fraction of the dose get into the bloodstream through the stomach wall. That's why oral doses are much larger in milligrams than injected ones, and why the timing rules are strict: take it on an empty stomach in the morning with up to 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other oral medicines. Check your own label for the exact instructions.
In the US it is sold for two uses. Rybelsus was approved in 2019 for type 2 diabetes. A reformulated version, Ozempic tablets, had its US launch announced for May 4, 2026 (external link), and one US label now covers both products. The Ozempic 1.5 mg starting tablet takes the place of Rybelsus 3 mg, and the 4 mg and 9 mg tablets match Rybelsus 7 mg and 14 mg. The strengths aren't interchangeable mg-for-mg, and the label only allows switching between the two after the first 30 days.
The Wegovy pill (oral semaglutide 25 mg) was approved on December 22, 2025 (external link) as the first oral GLP-1 for chronic weight management. In the OASIS 4 trial (external link), people taking it lost an average of 13.6% of their body weight at 64 weeks, compared with 2.2% on placebo. OASIS 4 had no injection arm. A Novo Nordisk-funded indirect comparison (external link) against the STEP 1 trial of injectable Wegovy 2.4 mg found weight loss comparable to the injection. See comparing the GLP-1 pills, the history of GLP-1 medications and manufacturer savings cards.
Both labels give the same water and timing rule: the Rybelsus and Ozempic tablets label (external link) and the Wegovy prescribing information (external link), which also lists salcaprozate sodium (SNAC) among the tablet's ingredients.